Related Experiment Video
Updated: Mar 11, 2026
05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
1.4K
Management of Obesity
Naji Alamuddin1, Zayna Bakizada1, Thomas A Wadden1
1All authors: Perelman School of Medicine, University of Pennsylvania Philadelphia, PA.
Summary
Intensive lifestyle interventions, medications, and bariatric surgery effectively promote significant weight loss and improve obesity-related health conditions. These approaches offer substantial benefits for managing obesity and related comorbidities.
Area of Science:
- Obesity and Metabolic Health
- Clinical Interventions
- Public Health
Background:
- Obesity is a complex chronic disease associated with numerous comorbidities.
- Effective weight management strategies are crucial for improving patient outcomes and reducing healthcare burdens.
Purpose of the Study:
- To review the efficacy of intensive lifestyle intervention, pharmacotherapy, and bariatric surgery for weight loss.
- To examine the impact of these interventions on obesity-related comorbidities.
Main Methods:
- Review of studies on intensive lifestyle interventions (diet, physical activity, behavior therapy).
- Analysis of data on pharmacotherapy for chronic weight management.
- Examination of outcomes from bariatric surgery procedures (Roux-en-Y gastric bypass, sleeve gastrectomy, adjustable gastric banding).
Main Results:
- Intensive lifestyle intervention yields 6-8% weight loss, improving type 2 diabetes progression, blood pressure, and triglyceride levels.
- Pharmacotherapy, as an adjunct to lifestyle intervention, increases weight loss by 2.5-8.9 kg.
- Bariatric surgery leads to long-term weight reduction (≥20%) and decreased morbidity/mortality.
Conclusions:
- Lifestyle intervention, pharmacotherapy, and bariatric surgery are effective strategies for significant weight loss and comorbidity management.
- Increased accessibility to these evidence-based treatments is needed for the millions of Americans suffering from obesity.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
1.2K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.2K
01:24Obesity
1.5K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.5K
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
340
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
340
01:21Drug Dosing: Obese Patients
323
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
323
01:26Atherosclerosis III: Management
541
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
541
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
259
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
259